Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Base-rate subscriptions are $A1450 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.


Download subscription form here



Latest News !

Dr Boreham's Crucible: Pro Medicus

Federal Election 2019: Policies & Comment

Orthocell Up 377% On 4-Patient Celgro Nerve Regeneration

Paradigm Raising $78m On PPS Osteoarthritis Pain Trial Results

Federal Budget 2019 - Comment & Analysis

Oncosil Falls 87% On Pancreatic Cancer Radiation Doubts

2018 - The Year In Review



April BDI-40 Up 18%, ASX200 Up 2%
Big Caps Up 3%, NBI Down 5%

 Volpara Up 49%, Antisense 44%, Polynovo 41%
Immutep Down 15
%, Patrys 11%


May 1, 2019

April was truly excellent for Australian biotechnology - one of the best months on record.
The Biotech Daily Top 40 Index (BDI-40) climbed 18.1 percent, again out-performing the ASX200 which was up 2.3 percent, while the Nasdaq Biotechnology Index (NBI) fell a further 4.8 percent.
The three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) rose a collective 2.9 percent in April.
For the year to April 30, 2019 the BDI-40 was up 20.9 percent, the ASX200 rose 5.7 percent, the Big Caps improved 14.5 percent and the NBI was up 2.7 percent.
In April, Cochlear improved 8.6 percent to $10,812 million, CSL rose 2.6 percent to $89,972 million and Resmed was up 1.5 percent to $21,019 million.
In April, 24 of the BDI-40 stocks were up; 17 by more than 10 percent and seven by more than 30 percent; while 11 fell, with just two losing more than 10 percent; and five were unchanged.
While Pro Medicus added $581 million to the index, Volpara was the best by percentage, up 48.7 percent for the month and 243.3 percent for the year to $333 million, followed by Antisense up 43.75 percent for the month and 360.0 percent for the year to $23 million.
Polynovo was up 40.7 percent, followed by Alterity (Prana) up 40 percent, Pro Medicus (37.8%), Avita (37.5%), Oncosil (36.0%), Starpharma (31.1%), Impedimed (20.7%), Mesoblast (18.4%), Nanosonics (14.6%), Universal Biosensors (14.3%), Medical Developments (13.9%), Cyclopharm (13.3%), Osprey (12.5%), Benitec (12.1%) and Pharmaxis (10.7%).
Immutep led the falls, down $17 million or 15.2 percent to $95 million, followed by Patrys (11.1%), Orthocell (8.3%), Uscom (8.0%), Dimerix (7.1%) and Imugene (5.8%).
Outside the Top 40, Acrux was at its best since September 2017, Resonance continued its record run, up a further 40.5 percent to $52 million, with Alcidion, Elixinol, Medadvisor, Painchek and Recce all contenders for promotion.
The 16 stocks in Cannabis Corner were up 5.1 percent to a collective market capitalization of $1,614 million, with 11 companies up, three down and two unchanged.
On the Nasdaq, Vaxart (Biota) was at an all-time low tumbling 60.9 percent on a capital raising to $9 million, Queensland’s Protagonist lost 17.6 percent to $341 million; Israel’s Redhill (with Australian assets) shed 5.4 percent to $314 million and Eyepoint (Psivida) fell 4.1 percent to $231 million.
There are some changes to the BDI-40 this month with Cynata, Genetic Signatures and Paradigm earning their promotions from the Second 20 to the Top 20, swapping places with Impedimed, LBT and Reva.

BDI-40 v S&P ASX200 Jun 30, 2006 to Apr 30, 2019 
Big Caps (Cochlear, CSL, Resmed) Apr 30, 2016 To Apr 30, 2019




 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At Apr 30, 2019


* Biotech Daily editor, David Langsam, owns shares in Acrux, Alterity, Amplia, Benitec, Cynata, Mesoblast
   Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: